Find comprehensive information on Proteus mirabilis infection diagnosis, including clinical documentation, medical coding (ICD-10 codes, SNOMED CT), laboratory testing, and treatment. Learn about symptoms, causes, and prevention of Proteus mirabilis UTI and other related infections. This resource is for healthcare professionals seeking guidance on accurate diagnosis and appropriate management of Proteus mirabilis.
Also known as
Other bacterial infections of unspecified site
Infection caused by Proteus mirabilis, unspecified location.
Urinary tract infection, site not specified
Proteus mirabilis UTI, location unspecified.
Other specified bacterial agents as the cause of diseases classified elsewhere
Proteus mirabilis causing a disease classified elsewhere.
Sepsis, unspecified organism
Sepsis potentially caused by Proteus mirabilis, without organism confirmation.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the Proteus mirabilis infection localized?
When to use each related code
| Description |
|---|
| Proteus mirabilis Infection |
| Escherichia coli Infection |
| Klebsiella pneumoniae Infection |
Coding Proteus mirabilis infection without specifying the infection site leads to inaccurate coding and reimbursement issues. Use specific ICD-10 codes like B96.2 for UTI.
Incorrectly coding sepsis due to Proteus mirabilis. Differentiate between localized infection and sepsis (A41.8) for accurate severity reflection.
Failing to document and code underlying conditions that increase susceptibility to Proteus mirabilis infection, such as diabetes or catheterization, impacts risk adjustment.
Q: What are the most effective antibiotic treatment strategies for complicated urinary tract infections (UTIs) caused by Proteus mirabilis, considering increasing antimicrobial resistance?
A: Complicated UTIs caused by Proteus mirabilis pose a therapeutic challenge due to increasing antimicrobial resistance, particularly to ampicillin and first-generation cephalosporins. Current guidelines recommend considering urine culture and sensitivity testing to guide antibiotic selection. For empiric treatment, options with activity against multi-drug resistant strains include fluoroquinolones (ciprofloxacin, levofloxacin) or trimethoprim-sulfamethoxazole (TMP-SMX) if local resistance rates are low. For severe infections or those failing initial therapy, carbapenems (ertapenem, imipenem, meropenem) or aminoglycosides (gentamicin, amikacin) may be necessary, often in consultation with an infectious disease specialist. Explore how antibiotic stewardship programs can optimize treatment strategies and minimize resistance development. Consider implementing rapid diagnostic testing to facilitate prompt and appropriate antibiotic selection in complicated UTIs. The duration of antibiotic therapy should be individualized based on the severity and location of the infection, typically ranging from 7 to 14 days. Learn more about the latest resistance patterns and guidelines for managing multi-drug resistant Proteus mirabilis.
Q: How can I differentiate Proteus mirabilis UTI from other common uropathogens based on clinical presentation and laboratory findings, especially in patients with underlying conditions like catheterization or urinary stones?
A: Differentiating Proteus mirabilis UTI from other uropathogens can be challenging as clinical presentations often overlap. However, certain clues can aid in suspicion. Proteus mirabilis is strongly associated with struvite stone formation and catheter-associated UTIs. Patients may present with more severe symptoms, including fever, flank pain, and hematuria, particularly with struvite stones or pyelonephritis. Urine odor may be distinctly ammoniacal due to urease production by Proteus mirabilis. Laboratory findings can be helpful. Urinalysis typically reveals alkaline urine pH, pyuria, and bacteriuria. Urine culture confirms the diagnosis and provides antimicrobial susceptibility testing, which is crucial given the potential for multi-drug resistance. Explore how advanced urine diagnostics, such as PCR or MALDI-TOF, can offer faster and more precise identification of Proteus mirabilis. Consider implementing standardized urine collection protocols to minimize contamination and improve diagnostic accuracy in catheterized patients. Learn more about the specific risks and management strategies for UTIs in patients with underlying urological conditions.
Patient presents with signs and symptoms suggestive of a Proteus mirabilis infection. Clinical presentation includes [specific symptoms e.g., fever, dysuria, urinary frequency, urgency, flank pain, malodorous urine, altered mental status in elderly patients]. Patient reports [onset and duration of symptoms]. Relevant medical history includes [e.g., recent urinary catheterization, indwelling catheter, neurogenic bladder, recurrent urinary tract infections, diabetes mellitus, kidney stones, recent hospitalization, antibiotic use]. Physical examination reveals [e.g., costovertebral angle tenderness, suprapubic tenderness, fever]. Urine dipstick demonstrates [e.g., positive leukocyte esterase, positive nitrites, hematuria]. Urine culture ordered to confirm Proteus mirabilis bacteriuria and assess antibiotic susceptibility. Preliminary diagnosis of Proteus mirabilis UTI, likely [cystitis, pyelonephritis, urosepsis, catheter-associated urinary tract infection] is established. Differential diagnosis includes other urinary tract pathogens. Treatment plan includes initiation of empiric antibiotic therapy with [specific antibiotic name and dosage] pending culture and sensitivity results. Patient education provided on medication administration, potential side effects, importance of completing the full course of antibiotics, and follow-up care. Patient instructed to increase fluid intake. Follow-up urine culture scheduled to assess treatment efficacy. ICD-10 code [N39.0, other codes as appropriate] and CPT codes for urinalysis, urine culture, and evaluation and management services will be documented for billing purposes. Plan to reassess patient in [ timeframe] to evaluate response to therapy. Patient with confirmed Proteus mirabilis infection based on positive urine culture. Antibiotic susceptibility testing indicates sensitivity to [list specific antibiotics]. Empiric antibiotic therapy is [continued, adjusted] based on susceptibility results. Patient reports [improvement, no improvement, worsening] in symptoms since initiation of therapy. Physical examination reveals [current findings]. Plan to continue current antibiotic regimen for [duration] and monitor for clinical response. Patient education reinforced regarding adherence to medication regimen, fluid intake, and recognition of potential complications such as urosepsis. Discussion of preventative measures for recurrent urinary tract infections including proper hygiene practices, avoidance of urinary catheters if possible, and prompt treatment of symptomatic infections. Follow-up appointment scheduled in [timeframe] or sooner if symptoms worsen. Continued monitoring for resolution of infection and potential complications. ICD-10 code [N39.0, other codes as appropriate] and CPT codes for follow-up evaluation and management will be documented.